Oral Exposure to Low Concentration of Fumonisin B2, but Not Fumonisin B1, Significantly Exacerbates the Pathophysiology of Imiquimod-Induced Psoriasis in Mice
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25147852 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mana Ando und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Veterinary Pharmacology, School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara City 252-5201, Kanagaw…. Hauptthemen laut MEDLINE: Psoriasis, Imiquimod, Fumonisins, Mice, Inbred BALB C. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Tojuro Iijima Foundation for Food Science and Technology, Tojuro Iijima Foundation for Food Science and Technology.
Abstract (Originalsprache)
This study aimed to determine whether oral fumonisin exposure contributes to the development of psoriasis. Oral administration of fumonisin B1 (FB1, 0.1 mg/kg) or fumonisin B2 (FB2, 0.1 mg/kg) was conducted for 10 days, in addition to the induction of psoriatic symptoms through topical application of 5% imiquimod cream from day 6 to day 10 (5 days) in female BALB/c mice. The results demonstrated that oral administration of FB2 significantly exacerbated psoriatic symptoms, including skin thickness, itching behavior, transepidermal water loss, immune cell infiltration in the dermis, and proinflammatory cytokine production. However, no changes were observed following exposure to FB1. Our results confirm that oral exposure to FB2 adversely affects the pathogenesis of psoriasis by increasing skin thickness and impairing barrier function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Veterinary Pharmacology, School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara City 252-5201, Kanagawa, Japan.
- Bioalch Co., Ltd., 3-28 Honshuku-cho, Fuchu City 183-0032, Tokyo, Japan.
- Japan SLC, Inc., 85 Ohara-cho, Chuo-Ku, Hamamatsu City 431-1103, Shizuoka, Japan.
- Division of Microbiology, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki City 210-9501, Kanagawa, Japan.
- Center for Human and Animal Symbiosis Science, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara City 252-5201, Kanagawa, Japan.
ORCID-Profile: Tomoki Fukuyama
Förderung
- The Tojuro Iijima Foundation for Food Science and Technology
- Tojuro Iijima Foundation for Food Science and Technology
Zitieren
APA
Ando, M., Yamaguchi, H., Iwashita, N., Takagi, Y., Yoshinari, T., & Fukuyama, T. (2024). Oral Exposure to Low Concentration of Fumonisin B2, but Not Fumonisin B1, Significantly Exacerbates the Pathophysiology of Imiquimod-Induced Psoriasis in Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147852
Vancouver
Ando M, Yamaguchi H, Iwashita N, Takagi Y, Yoshinari T, Fukuyama T. Oral Exposure to Low Concentration of Fumonisin B2, but Not Fumonisin B1, Significantly Exacerbates the Pathophysiology of Imiquimod-Induced Psoriasis in Mice. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147852
BibTeX
@article{Ando2024,
author = {Ando, Mana and Yamaguchi, Hiroki and Iwashita, Naoki and Takagi, Yoshiichi and Yoshinari, Tomoya and Fukuyama, Tomoki},
title = {Oral Exposure to Low Concentration of Fumonisin B2, but Not Fumonisin B1, Significantly Exacerbates the Pathophysiology of Imiquimod-Induced Psoriasis in Mice},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25147852}
}
EUVIMED